你即將離開本站

並前往https://nn.neurology.org/content/6/3/e548

Real-world persistence and benefit–risk profile of fingolimod ...

Fingolimod (Gilenya, Novartis Pharma AG, Basel, Switzerland) is approved in Europe for second-line use in patients with relapsing MS (RMS) or ...

確定！ 回上一頁

查詢 「Fingolimod」的人也找了：

  1. fingolimod仿單
    2.
  2. fingolimod中文
    3.
  3. fingolimod副作用
    4.
  4. Gilenya
    5.
  5. Multiple sclerosis
    6.
  6. fingolimod阿摩
    7.
  7. multiple sclerosis中文
    8.
  8. Fingolimod
    9.